Prior exposure to THC increases the addictive effects of nicotine in rats

Neuropsychopharmacology

Volumn 38, Issue 7, 2013, Pages 1198-1208

  Panlilio, Leigh V ^a   Zanettini, Claudio ^a,b   Barnes, Chanel ^a   Solinas, Marcelo ^c,d   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b University of Texas Health Science Center   (United States)

^c INSERM   (France)

^d UNIVERSITÉ DE POITIERS   (France)

Author keywords

behavioral economics; cannabis; gateway drug hypothesis; light dark test; open field; self administration

Indexed keywords

CANNABIS; COCAINE; DIAMORPHINE; DRONABINOL; NICOTINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CANNABIS ADDICTION; CATHETERIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG EXPOSURE; DRUG SELF ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ADDICTIVE; CANNABINOID RECEPTOR AGONISTS; CONDITIONING, OPERANT; DRONABINOL; DRUG SYNERGISM; MALE; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; RATS; REINFORCEMENT SCHEDULE; REWARD; SELF ADMINISTRATION;

EID: 84878580882     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.16     Document Type: Article

References (80)

1. Adriani W, Deroche-Gamonet V, Le Moal M, Laviola G, Piazza PV (2006). Preexposure during or following adolescence differently affects nicotine-rewarding properties in adult rats. Psychopharmacology (Berl) 184: 382-390.
2. Agrawal A, Budney AJ, Lynskey MT (2012). The co-occurring use and misuse of cannabis and tobacco: a review. Addiction 107: 1221-1233.
3. Agrawal A, Madden PA, Bucholz KK, Heath AC, Lynskey MT (2008). Transitions to regular smoking and to nicotine dependence in women using cannabis. Drug Alcohol Depend 95: 107-114.
4. Agrawal A, Scherrer JF, Lynskey MT, Sartor CE, Grant JD, Haber JR et al (2011). Patterns of use, sequence of onsets and correlates of tobacco and cannabis. Addict Behav 36: 1141-1147.
5. Amos A, Wiltshire S, Bostock Y, Haw S, McNeill A (2004). 'You can't go without a fag. you need it for your hash'-a qualitative exploration of smoking, cannabis and young people. Addiction 99: 77-81.
6. Anthony JC, Warner LA, Kessler RC (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol 2: 244-268.
7. Berrendero F, Robledo P, Trigo JM, Mart?n-Garc?a E, Maldonado R (2010). Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev 35: 220-231.
8. Bruijnzeel AW, Markou A (2003). Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 50: 20-28.
9. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G (2001). Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology (Berl) 158: 259-266.
10. Cahill K, Ussher M (2007). Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007: CD005353.
11. Castane A, Berrendero F, Maldonado R (2005). The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav 81: 381-386.
12. Chaudhri N, Caggiula AR, Donny EC, Booth S, Gharib M, Craven L et al (2007). Self-administered and noncontingent nicotine enhance reinforced operant responding in rats: impact of nicotine dose and reinforcement schedule. Psychopharmacology (Berl) 190: 353-362.
13. Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y (2009). A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 104: 266-276.
14. Coen KM, Adamson KL, Corrigall WA (2009). Medication-related pharmacological manipulations of nicotine self-administration in the rat maintained on fixed-and progressive-ratio schedules of reinforcement. Psychopharmacology (Berl) 201: 557-568.
15. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002). SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13: 451-463.
16. Corrigall WA (1991). A rodent model for nicotine self-administration. In: Boulton A, Baker GB, Wu PH (eds). Animal Models of Drug Addiction. Neuromethods Vol 21 (Humana: Clifton, NJ), pp 315-344.
17. Corrigall WA, Coen KM, Zhang J, Adamson KL (2001). GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology (Berl) 158: 190-197.
18. Corrigall WA, Franklin KB, Coen KM, Clarke PB (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 107: 285-289.
19. Degenhardt L, Chiu WT, Conway K, Dierker L, Glantz M, Kalaydjian A et al (2009). Does the 'gateway' matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. Psychol Med 39: 157-167.
20. Donny EC, Caggiula AR, Mielke MM, Jacobs KS, Rose C, Sved AF (1998). Acquisition of nicotine self-administration in rats: the effects of dose, feeding schedule, and drug contingency. Psychopharmacology (Berl) 136: 83-90.
21. Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH et al (2008). Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 18: 826-834.
22. Ellgren M, Spano SM, Hurd YL (2007). Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32: 607-615.
23. Fergusson DM, Boden JM, Horwood LJ (2006). Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 101: 556-569.
24. Forget B, Hamon M, Thiebot MH (2005). Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl) 181: 722-734.
25. Freeman KB, Woolverton WL (2009). Self-administration of cocaine and nicotine mixtures by rhesus monkeys. Psychopharmacology (Berl) 207: 99-106.
26. Gamaleddin I, Wertheim C, Zhu AZ, Coen KM, Vemuri K, Makryannis A et al (2012). Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol 17: 47-61.
27. Gerber GJ, Wise RA (1989). Pharmacological regulation of intravenous cocaine and heroin self-administration in rats: a variable dose paradigm. Pharmacol Biochem Behav 32: 527-531.
28. Gould RW, Czoty PW, Nader SH, Nader MA (2011). Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 339: 678-686.
29. Hadjiconstantinou M, Neff NH (2011). Nicotine and endogenous opioids: neurochemical and pharmacological evidence. Neuropharmacology 60: 1209-1220.
30. Hall WD, Lynskey M (2005). Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev 24: 39-48.
31. Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR (2004). Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) 175: 134-142.
32. Hursh SR, Silberberg A (2008). Economic demand and essential value. Psychol Rev 115: 186-198.
33. Kandel DB (1975). Stages in adolescent involvement in drug use. Science 190: 912-914.
34. Kandel DB, Yamaguchi K, Chen K (1992). Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. J Stud Alcohol 53: 447-457.
35. Kandel DB, Yamaguchi K, Klein LC (2006). Testing the gateway hypothesis. Addiction 101: 470-472.
36. Le Foll B, Forget B, Aubin HJ, Goldberg SR (2008). Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 13: 239-252.
37. Le Foll B, Goldberg SR (2004). Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15: 2139-2143.
38. Le Foll B, Goldberg SR (2009). Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol 192: 335-367.
39. Lee JP, Battle RS, Lipton R, Soller B (2010). 'Smoking': use of cigarettes, cigars and blunts among Southeast Asian American youth and young adults. Health Educ Res 25: 83-96.
40. MacCoun R (1998). In what sense (if any) is marijuana a gateway drug? Drug Policy Anal Bull 4: 5-8.
41. MacCoun RJ (2006). Competing accounts of the gateway effect: the field thins, but still no clear winner. Addiction 101: 473-474.
42. Mackay J, Eriksen M (2002). The Tobacco Atlas. World Health Organization: Geneva.
43. Maldonado R (2002). Study of cannabinoid dependence in animals. Pharmacol Ther 95: 153-164.
44. Mart?n-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya S, Allen P et al (2010). Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 40: 383-398.
45. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S et al (2011). Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 69: 633-641.
46. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP et al (2005). Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436: 103-107.
47. Mello NK, Newman JL (2011). Discriminative and reinforcing stimulus effects of nicotine, cocaine, and cocainenicotine combinations in Rhesus Monkeys. Exp Clin Psychopharmacol 19: 203-214.
48. Morral AR, McCaffrey DF, Paddock SM (2002). Reassessing the marijuana gateway effect. Addiction 97: 1493-1504.
49. Palmatier MI, Liu X, Caggiula AR, Donny EC, Sved AF (2007). The role of nicotinic acetylcholine receptors in the primary reinforcing and reinforcement-enhancing effects of nicotine. Neuropsychopharmacology 32: 1098-1108.
50. Panlilio LV, Justinova Z, Mascia P, Pistis M, Luchicchi A, Lecca S et al (2012). Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. Neuropsychopharmacology 37: 1838-1847.
51. Panlilio LV, Schindler CW (2000). Self-administration of remifentanil, an ultra-short acting opioid, under continuous and progressive-ratio schedules of reinforcement in rats. Psychopharmacology (Berl) 150: 61-66.
52. Panlilio LV, Solinas M, Matthews SA, Goldberg SR (2007). Previous exposure to THC alters the reinforcing efficacy and anxietyrelated effects of cocaine in rats. Neuropsychopharmacology 32: 646-657.
53. Panlilio LV, Thorndike EB, Schindler CW (2008). A stimuluscontrol account of regulated drug intake in rats. Psychopharmacology (Berl) 196: 441-450.
54. Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M (2005). Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100: 1518-1525.
55. Peartree NA, Sanabria F, Thiel KJ, Weber SM, Cheung TH, Neisewander JL (2012). A new criterion for acquisition of nicotine self-administration in rats. Drug Alcohol Depend 124: 63-69.
56. Prescot AP, Locatelli AE, Renshaw PF, Yurgelun-Todd DA (2011). Neurochemical alterations in adolescent chronic marijuana smokers: a proton MRS study. Neuroimage 57: 69-75.
57. Risner ME, Goldberg SR (1983). A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J Pharmacol Exp Ther 224: 319-326.
58. Ross JT, Corrigall WA, Heidbreder CA, LeSage MG (2007). Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 559: 173-179.
59. Rubino T, Forlani G, Vigano D, Zippel R, Parolaro D (2004). Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci 25: 355-362.
60. Rubino T, Vigano D, Massi P, Parolaro D (2003). Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioural sensitization. Eur J Neurosci 17: 325-330.
61. Scherma M, Panlilio LV, Fadda P, Fattore L, Gamaleddin I, Le Foll B et al (2008). Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther 327: 482-490.
62. Schweinsburg AD, Brown SA, Tapert SF (2008). The influence of marijuana use on neurocognitive functioning in adolescents. Curr Drug Abuse Rev 1: 99-111.
63. Shoaib M (2008). The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 52: 438-444.
64. Shoaib M, Schindler CW, Goldberg SR (1997). Nicotine selfadministration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) 129: 35-43.
65. Shoaib M, Swanner LS, Yasar S, Goldberg SR (1999). Chronic caffeine exposure potentiates nicotine self-administration in rats. Psychopharmacology (Berl) 142: 327-333.
66. Siqueira LM, Brook JS (2003). Tobacco use as a predictor of illicit drug use and drug-related problems in Colombian youth. J Adolesc Health 32: 50-57.
67. Solinas M, Goldberg SR, Piomelli D (2008). The endocannabinoid system in brain reward processes. Br J Pharmacol 154: 369-383.
68. Solinas M, Panlilio LV, Goldberg SR (2004). Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats. Neuropsychopharmacology 29: 1301-1311.
69. Stapleton J (1998). Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res 7: 187-203.
70. Tarter RE, Vanyukov M, Kirisci L, Reynolds M, Clark DB (2006). Predictors of marijuana use in adolescents before and after licit drug use: examination of the gateway hypothesis. Am J Psychiatry 163: 2134-2140.
71. Timberlake DS, Haberstick BC, Hopfer CJ, Bricker J, Sakai JT, Lessem JM et al (2007). Progression from marijuana use to daily smoking and nicotine dependence in a national sample of U.S. adolescents. Drug Alcohol Depend 88: 272-281.
72. Tullis LM, Dupont R, Frost-Pineda K, Gold MS (2003). Marijuana and tobacco: a major connection? J Addict Dis 22: 51-62.
73. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R (2002). Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135: 564-578.
74. Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ et al (2012). Common liability to addiction and 'gateway hypothesis': theoretical, empirical and evolutionary perspective. Drug Alcohol Depend 123: S3-S17.
75. VaughnM,Wallace J, Perron B, Copeland V, HowardM (2008). Does marijuana use serve as a gateway to cigarette use for high-risk African-American youth? Am J Drug Alcohol Abuse 34: 782-791.
76. Vigano D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C et al (2005). Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) 182: 527-536.
77. Viveros MP, Marco EM, File SE (2006). Nicotine and cannabinoids: parallels, contrasts and interactions. Neurosci Biobehav Rev 30: 1161-1181.
78. Wagner FA, Anthony JC (2002). Into the world of illegal drug use: exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am J Epidemiol 155: 918-925.
79. Wells JE, McGee MA (2008). Violations of the usual sequence of drug initiation: prevalence and associations with the development of dependence in the New Zealand Mental Health Survey. J Stud Alcohol Drugs 69: 789-795.
80. Werling LL, Reed SC, Wade D, Izenwasser S (2009). Chronic nicotine alters cannabinoid-mediated locomotor activity and receptor density in periadolescent but not adult male rats. Int J Dev Neurosci 27: 263-269.